Difference between revisions of "Mirtazapine-paroxetine"

From Psychiatrienet
Jump to: navigation, search
(Created page with '{{Drugswitch | from = mirtazapine | to = paroxetine | stop = * '''Day 0:''' gradually reduce dosage of duloxetine to a maximum of 30 mg/ day. * '''Day 1:''' reduce a dosage o...')
(No difference)

Revision as of 20:39, 5 May 2009

Mirtazapine
Type Antidepressant
Group other
links
Medscape Mirtazapine
PubChem 4205
PubMed Mirtazapine
Kompas (Dutch) Mirtazapine
Wikipedia Mirtazapine
paroxetine
Type Antidepressant
Group SSRI
links
Medscape paroxetine
PubChem 43815
PubMed paroxetine
Kompas (Dutch) paroxetine
Wikipedia paroxetine

Switch medication from mirtazapine to paroxetine.[1] [2]

Nietinrijdenbord.png Stop mirtazapine
  • Day 0: gradually reduce dosage of duloxetine to a maximum of 30 mg/ day.
  • Day 1: reduce a dosage of 30 mg/day to 15 mg/day.
Eenrichtingbord.png Start paroxetine
  • Day 1: simultaneously start paroxetine in a normal dosage of 20 mg/day.
  • Day 8: stop administration of mirtazapine and only continue administration of paroxetine.


  1. Switches are based on literature references on this page and expert opinions of the authors. The authors have used pharmacokinetic and receptor affinity properties to determine the switch schedules
  2. Stahl, S. M. (2013). Stahl's essential psychopharmacology: Neuroscientific basis and practical applications (4th ed.). Cambridge University Press.
The editors of psychiatrienet.nl take the greatest care to provide up-to-date and accurate information on this site. Nevertheless, mistakes and omissions cannot be entirely excluded. No rights devolve from the information provided. The editors and other providers of information to this site accept no responsibility for the content of this site or for the information provided therein; neither do they accept responsibility for possible damages which may derive from the use of the information on this site or from the linked sites. The editorial board accepts no responsibility for the content of the (linked) sites, for access to them, or for the products and services on these sites, nor for the occurrence of errors, viruses, and/or disruptions in service.